Diabetes, Medication Management
Type 2 Diabetes and Pharmacotherapy: Should Metformin Remain the First-Line Treatment?
This is a short microlearning for Canadian healthcare professionals. This video is designed to provide healthcare professionals with knowledge on the evolving role of metformin and newer agents, such as SGLT2 inhibitors and GLP-1 receptor agonists, in the management of type 2 diabetes.
DURATION
10 min
PROFESSION
Physician, Nursing, Pharmacy, Allied Health, Medical Resident, Student, Specialist
# OF CREDITS
0
ACCREDITATION
Unaccredited
EXPIRY DATE
2025-10-01
In this video, Dr. Ronald Goldenberg, an endocrinologist at LMC Diabetes and Endocrinology, discusses the evolving landscape of first-line therapy for type 2 diabetes. He reviews the historical role of metformin, the impact of landmark trials such as the UK Prospective Diabetes Study and explores the potential benefits of newer agents like SGLT2 inhibitors and GLP-1 receptor agonists, emphasizing individualized treatment approaches based on patient profiles and comorbidities.
Faculty
Ronald Goldenberg, MD, FRCPC, FACE
Learning objectives
After viewing this expert brief, participants will be better able to:
- Understand the historical role of metformin in type 2 diabetes management and the evidence supporting its use
- Evaluate the cardio-renal benefits and glucose-lowering effects of newer agents, such as SGLT2 inhibitors and GLP-1 receptor agonists
- Analyze the evolving guidelines and recommendations for individualizing first-line therapy based on patient comorbidities and risk factors
#
of credits: 0
Duration: 10 min
FAQs & HELP
MDBriefCase Group specializes in accredited, online continuing professional development (CPD) programs, custom tailored for specific international markets and available on a convenient online platform.
All content is developed by leading specialists and peer-reviewed by experts at respected institutions, which keeps more than 280,000 global healthcare professionals at the forefront of the latest evidence and protocols worldwide.
The vast majority of our programs are accredited by one or more respected institutions. We do provide unaccredited content to ensure that healthcare professionals have access to relevant practical resources in addition to accredited learning.
Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.
MDBriefCase Group works with various institutions to provide peer-reviewed, up-to-date accredited content. Our programs and resources are provided via collaboration between medical writers, faculty members, associations, universities and other relevant organizations. The content you were recommended is likely valued by your society or association and is conveniently provided to you free of charge on an MDBriefCase Group platform.
Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.
If you are interested in learning more about supporting one of our programs, please contact us.
If you are interested in working with MDBriefCase Group as a writer or committee member, please contact us.
To access the MDBriefCase Group privacy policy, please click here.
No, registration with MDBriefCase is free!
To access your profile, visit My Profile. If you would like to update the information here don’t forget to hit the ‘save’ button when you are finished. Your profile is where you can control what email communications you receive.
If you have forgotten your password, you can reset your password. To access this page from the Login page, click Forgot password. Enter the email address you registered with and you will receive an email with a link to reset your password.
Please note: if you submitted multiple password resets, only the link on the most recent email is valid.
You can unsubscribe from MDBriefCase Group emails by clicking the unsubscribe button located at the bottom of each of our emails.
10 min
Duration
Physician, Nursing, Pharmacy, Allied Health, Medical Resident, Student, Specialist
Profession
0
# of credits
Learning Objectives
After viewing this expert brief, participants will be better able to:
- Understand the historical role of metformin in type 2 diabetes management and the evidence supporting its use
- Evaluate the cardio-renal benefits and glucose-lowering effects of newer agents, such as SGLT2 inhibitors and GLP-1 receptor agonists
- Analyze the evolving guidelines and recommendations for individualizing first-line therapy based on patient comorbidities and risk factors
Unaccredited
ACCREDITATION
Diabetes, Medication Management
Learning Category
Diabetes
Topic
0
Price
2025-10-01
Expiry Date
CAN-eng
Region/Language
Course Description
In this video, Dr. Ronald Goldenberg, an endocrinologist at LMC Diabetes and Endocrinology, discusses the evolving landscape of first-line therapy for type 2 diabetes. He reviews the historical role of metformin, the impact of landmark trials such as the UK Prospective Diabetes Study and explores the potential benefits of newer agents like SGLT2 inhibitors and GLP-1 receptor agonists, emphasizing individualized treatment approaches based on patient profiles and comorbidities.
Faculty
Ronald Goldenberg, MD, FRCPC, FACE
Accreditation
10 min
Duration
0
Price
0
# of credits
